CRS Plus HIPEC Outperforms CRS Alone in Quality of Life for Cancer Patients

Patients with colorectal cancer receiving cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS plus HIPEC) experience significantly improved quality of life (QoL) compared to those undergoing CRS alone. Results indicate a notable minimal clinically important difference (MCID) favoring the HIPEC group, with improvement often evident within three months. Deterioration in MCID correlates with factors such as surgical approach, age, sex, and preoperative QoL, underscoring the importance of tailored preoperative strategies.